Lannett launches Cediprof's Synthroid generic

Lannett is launching Cediprof’s generic Synthroid (levothyroxine sodium) tablets, under the companies' recently announced interim exclusive supply and distribution agreement.

The companies said they have prevailed in separate legal challenges by Cediprof's previous distributor of the product. Judges in two courts denied a request by the previous distribution partner for a temporary restraining order that sought to enjoin Cediprof from terminating the prior agreement and transferring distribution rights to Lannett.

Lannett said the rulings removed a potential hurdle for it to commence distributing the product in the United States, notwithstanding any ongoing dispute with Cediprof's prior partner on the earlier termination.

Cediprof is a part of the Neolpharma Pharmaceutical Group family of companies.